Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

Kaat De Clercq, Feifan Xie, Olivier De Wever, Benedicte Descamps, Anne Hoorens, An Vermeulen, Wim Ceelen, Chris Vervaet

Scientific Reports · 2019 · 38 citations · 59 references

DOIFull text

Open access

Concepts

Abstract

Abstract Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics. Paclitaxel-loaded genipin-crosslinked gelatin microspheres (PTX-GP-MS) are evaluated for the treatment of microscopic peritoneal carcinomatosis and prevention of recurrent disease. The highest drug load (39.2 µg PTX/mg MS) was obtained by immersion of GP-MS in aqueous PTX nanosuspension (PTX nano -GP-MS) instead of ethanolic PTX solution (PTX EtOH -GP-MS). PTX release from PTX-GP-MS was prolonged. PTX nano -GP-MS displayed a more controlled release compared to a biphasic release from PTX EtOH -GP-MS. Anticancer efficacy of IP PTX-GP-MS (PTX EtOH -GP-MS, D = 7.5 mg PTX/kg; PTX nano -GP-MS D = 7.5 and 35 mg PTX/kg), IP nanoparticular albumin-bound PTX (D = 35 mg PTX/kg) and controls (0.9% NaCl, blank GP-MS) was evaluated in a microscopic peritoneal carcinomatosis xenograft mouse model. PTX nano -GP-MS showed superior anticancer efficacy with significant increased survival time, decreased peritoneal carcinomatosis index score and ascites incidence. However, prolonged PTX release over 14 days from PTX nano -GP-MS caused drug-related toxicity in 27% of high-dosed PTX nano -GP-MS-treated mice. Dose simulations for PTX nano -GP-MS demonstrated an optimal survival without drug-induced toxicity in a range of 7.5–15 mg PTX/kg. Low-dosed PTX nano -GP-MS can be a promising IP drug delivery system to prevent recurrent ovarian cancer.

References

59